RT Journal Article SR Electronic T1 Current Approaches for Absorption, Distribution, Metabolism, and Excretion Characterization of Antibody-Drug Conjugates: An Industry White Paper JF Drug Metabolism and Disposition JO Drug Metab Dispos FD American Society for Pharmacology and Experimental Therapeutics SP 617 OP 623 DO 10.1124/dmd.115.068049 VO 44 IS 5 A1 Eugenia Kraynov A1 Amrita V. Kamath A1 Markus Walles A1 Edit Tarcsa A1 Antoine Deslandes A1 Ramaswamy A. Iyer A1 Amita Datta-Mannan A1 Priya Sriraman A1 Michaela Bairlein A1 Johnny J. Yang A1 Matthew Barfield A1 Guangqing Xiao A1 Enrique Escandon A1 Weirong Wang A1 Dan A. Rock A1 Nagendra V. Chemuturi A1 David J. Moore YR 2016 UL http://dmd.aspetjournals.org/content/44/5/617.abstract AB An antibody-drug conjugate (ADC) is a unique therapeutic modality composed of a highly potent drug molecule conjugated to a monoclonal antibody. As the number of ADCs in various stages of nonclinical and clinical development has been increasing, pharmaceutical companies have been exploring diverse approaches to understanding the disposition of ADCs. To identify the key absorption, distribution, metabolism, and excretion (ADME) issues worth examining when developing an ADC and to find optimal scientifically based approaches to evaluate ADC ADME, the International Consortium for Innovation and Quality in Pharmaceutical Development launched an ADC ADME working group in early 2014. This white paper contains observations from the working group and provides an initial framework on issues and approaches to consider when evaluating the ADME of ADCs.